Tim Wentworth

Pharmacy chain amid severe industry headwinds. Walgreens operates over 8,500 stores in the United States (under the Walgreens banner) and approximately 3,600 stores internationally (primarily Boots in the UK). The company dispenses approximately 20% of all retail prescriptions in the United States. The retail pharmacy business model is under intense pressure: pharmacy reimbursement rates are being squeezed by pharmacy benefit managers (PBMs), front-of-store retail sales are declining as consumers shift to e-commerce, and competition from CVS Health, Amazon Pharmacy, and cost-plus pharmacy disruptors is intensifying. Walgreens has been closing hundreds of underperforming stores and cutting costs. Walgreens invested heavily in VillageMD (primary care clinics co-located in stores) and other healthcare ventures as part of a strategy to transform from a pharmacy retailer into a healthcare delivery company. However, these investments have consumed significant capital with uncertain returns. Key stock drivers include pharmacy reimbursement rates, prescription volume growth, store closure program and cost savings, VillageMD clinic performance and path to profitability, front-of-store retail trends, debt reduction, competition with CVS and Amazon, and the broader transformation of U.S. pharmacy into healthcare services.